Current Concepts and Recent Advances in Oncology:
A Daylong Clinical Summit
Hosted in Partnership with MOASC

A CME-MOC/NCPD Accredited Virtual Event

Moderated by Neil Love, MD

Saturday, March 6, 2021
7:30am – 3:30pm PT (10:30am – 6:30pm ET) *tentative schedule*

Project details for your consideration are as follows:

- Submission of a handful of brief case write-ups from your practice. *Specifics regarding these case requests will be sent by mid-January 2021. Select cases will require additional information including pathology/imaging.*
- Participation in a 1-hour, one-on-one video/audio recording (virtual) session from your home or office with Dr Love in which you will deliver and discuss your cases. Recorded video clips from this discussion will be shown during the live webinar on March 6.
- As a reference, below are a list of malignancies that will be discussed during the virtual program.
- We would like to request that you let us know which of these listed you would feel comfortable discussing. Once we have this information from you, we'll tailor the case request accordingly.
- **The case discussion interview must be completed prior to February 5, 2021.**
- *Additionally, we will need to conduct a 15-minute Zoom run-through call with you and our Audio Engineer prior to your roundtable session if you have not completed already for a previous project with* us.

For your participation, an honorarium of $2,500 will be provided.

General Case Requirements:

Specifics regarding these case requests will be sent by mid-January 2021

Breast Cancer
- HER2-positive – *localized or metastatic*
- ER-positive, HER2-negative – *localized or metastatic*
- Triple-negative breast cancer – *localized or metastatic*

CLL and Lymphomas
- CLL
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Hodgkin lymphoma

GI Cancers
- CRC – *metastatic*
- Gastric cancer - *metastatic*
- Hepatocellular cancer – *advanced*
- Pancreatic cancer – *localized or metastatic*
- Cholangiocarcinoma – *advanced*

GU Cancers
- Prostate cancer – *M0, metastatic CRPC & HSPC*
- Renal cell carcinoma – *advanced*
- Urothelial bladder cancer – *metastatic*

Gynecologic Cancers
- Ovarian cancer
  - BRCA/HRD positive; BRCA negative
  - Multiply relapsed
- Cervical cancer – relapsed
  - PD-L1 positive
- Endometrial cancer – relapsed
  - MSI-H and MSS

Lung Cancer
- Non-small cell lung cancer (NSCLC)
  - Early stage or metastatic NSCLC with a targetable mutation (EGFR, ALK, etc)
  - Locally advanced or metastatic NSCLC who received immunotherapy
- Extensive stage small cell lung cancer

Multiple Myeloma
- Newly diagnosed or relapsed